Recruitment

Recruitment Status
Unknown status

Inclusion Criteria

18 years or older
clinical diagnosis of borderline personality disorder
if on psychiatric medication, must be on a stable dose
...
18 years or older
clinical diagnosis of borderline personality disorder
if on psychiatric medication, must be on a stable dose
able to swallow tablets

Exclusion Criteria

Conditions that can affect immune system functioning.
history or current psychotic disorder
current, primary substance abuse, particularly alcoholism
...
Conditions that can affect immune system functioning.
history or current psychotic disorder
current, primary substance abuse, particularly alcoholism
suicidal ideation or behavior requiring imminent inpatient treatment
Impaired liver function (> 1.25x the upper limit of the reference range)
pregnancy
current eating disorder
Participants whose medication has not been stable for more than 4 weeks

Summary

Conditions
Borderline Personality Disorder
Type
Interventional
Phase
Phase 2
Design
  • Allocation: Non-Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Basic Science

Participation Requirements

Age
Between 18 years and 50 years
Gender
Only females

Inclusion Criteria

18 years or older
clinical diagnosis of borderline personality disorder
if on psychiatric medication, must be on a stable dose
...
18 years or older
clinical diagnosis of borderline personality disorder
if on psychiatric medication, must be on a stable dose
able to swallow tablets

Exclusion Criteria

Conditions that can affect immune system functioning.
history or current psychotic disorder
current, primary substance abuse, particularly alcoholism
...
Conditions that can affect immune system functioning.
history or current psychotic disorder
current, primary substance abuse, particularly alcoholism
suicidal ideation or behavior requiring imminent inpatient treatment
Impaired liver function (> 1.25x the upper limit of the reference range)
pregnancy
current eating disorder
Participants whose medication has not been stable for more than 4 weeks

Tracking Information

NCT #
NCT02108990
Collaborators
National Center for Advancing Translational Science (NCATS)
Investigators
  • Principal Investigator: Baldwin M Way, Ph.D. Ohio State University Principal Investigator: Jennifer S. Cheavens, Ph.D. Ohio State University
  • Baldwin M Way, Ph.D. Ohio State University Principal Investigator: Jennifer S. Cheavens, Ph.D. Ohio State University